drugset / Trial / NCT02175485

Evaluation of Efficacy of Dellegra in Exposure Unit

NCT02175485

Phase 4 Completed 24 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To collect and analyze clinical data of Allergic Rhinitis patients' Total Nasal Symptom Score (TNSS) change after Dellegra internal use under high density pure Japanese cedar pollen exposure. Secondary Objective: To collect and analyze clinical data of Allergic Rhinitis patients' change in Total Symptom Score (TSS) and amount of nasal discharge, safety, and overall patients' impression about efficacy of Dellegra after Dellegra internal use under high density pure Japanese cedar pollen exposure.

Timeline

Start
2014-06
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 60 mg Oral
Subject Pseudoephedrine Small molecule 120 mg Oral

Indications